These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 20960451)
1. Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Chen H; Pimienta G; Gu Y; Sun X; Hu J; Kim MS; Chaerkady R; Gucek M; Cole RN; Sukumar S; Pandey A Proteomics; 2010 Nov; 10(21):3800-10. PubMed ID: 20960451 [TBL] [Abstract][Full Text] [Related]
2. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
3. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707 [TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling of cancer stem cells derived from primary tumors of HER2/Neu transgenic mice. Kanojia D; Zhou W; Zhang J; Jie C; Lo PK; Wang Q; Chen H Proteomics; 2012 Nov; 12(22):3407-15. PubMed ID: 22997041 [TBL] [Abstract][Full Text] [Related]
5. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101 [TBL] [Abstract][Full Text] [Related]
6. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Jacquemart IC; Springs AE; Chen WY Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488 [TBL] [Abstract][Full Text] [Related]
7. Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Menon R; Omenn GS Cancer Res; 2010 May; 70(9):3440-9. PubMed ID: 20388783 [TBL] [Abstract][Full Text] [Related]
8. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982 [TBL] [Abstract][Full Text] [Related]
9. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Balavenkatraman KK; Aceto N; Britschgi A; Mueller U; Bence KK; Neel BG; Bentires-Alj M Mol Cancer Res; 2011 Oct; 9(10):1377-84. PubMed ID: 21849469 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis. Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710 [TBL] [Abstract][Full Text] [Related]
11. Promotion of breast cancer by beta-hexachlorocyclohexane in MCF10AT1 cells and MMTV-neu mice. Wong PS; Matsumura F BMC Cancer; 2007 Jul; 7():130. PubMed ID: 17640349 [TBL] [Abstract][Full Text] [Related]
12. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747 [TBL] [Abstract][Full Text] [Related]
13. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149 [TBL] [Abstract][Full Text] [Related]
14. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Bentires-Alj M; Neel BG Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513 [TBL] [Abstract][Full Text] [Related]
16. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Wilson KS; Roberts H; Leek R; Harris AL; Geradts J Am J Pathol; 2002 Oct; 161(4):1171-85. PubMed ID: 12368191 [TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mosley JD; Poirier JT; Seachrist DD; Landis MD; Keri RA Mol Cancer Ther; 2007 Aug; 6(8):2188-97. PubMed ID: 17699716 [TBL] [Abstract][Full Text] [Related]
18. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756 [TBL] [Abstract][Full Text] [Related]
19. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967 [TBL] [Abstract][Full Text] [Related]
20. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses. Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]